We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Donors Screened for Human Leukocyte Antigen Antibodies

By LabMedica International staff writers
Posted on 10 Jan 2011
Male blood donors have been screened by two serum tests to determine if they had antibodies to human leukocytes antigens (HLA), which may cause harm to the recipient. More...


The donor serum samples were initially screened for HLA class I and/or class II antibodies with a panel of fluorescent beads coated with HLA class I and class II antigen preparations using multiplex technology and an enzyme linked immunoassay-based method.

In a study carried out at the University of Texas (Houston, TX, USA), the fluorescent bead test (Luminex; Austin, TX, USA), confirmed that 33 donors were positive for HLA class I and/or II antibodies. The agreement rates between the methods for HLA class I and II antibodies were 21% (7/33) and 6% (2/33), respectively. The DonorScreen ELISA-based method, (GTI; Waukesha, WI, USA), was significantly more specific for HLA class I antibodies than for HLA class II antibodies. A false-positive result was reported for the HLA class I antibody in 2/33 (6%) of the donors and for the HLA class II antibody in 19/33 (58%) of the donors using the DonorScreen method.

A retrospective review of recipients of packed red blood cells (RBCs) and platelets processed from these 33 HLA-immunized male donors were conducted to identify transfusion-related acute lung injury (TRALI) and cognate antigens. HLA antibodies in the male donors corresponding to cognate antigens were found in two recipients of packed RBCs and in three recipients of platelets. Of eight donors positive for HLA antibodies, five did not have a history of blood transfusion.

Transfusion of virtually all blood products is implicated as a cause of TRALI, which can occurs within six hours of receipt of the product. In addition to infusion of packed RBCs, platelets, and fresh frozen plasma, transfusion of allogeneic stem cells and intravenous administration of immunoglobulin, and granulocytes have been implicated as causes of TRALI. The authors concluded that the ELISA method was too sensitive and had a high false-positive rate for the detection of HLA class II antibodies, and therefore excluding possible donors. The study was published in January 2011 in the American Journal of Clinical Pathology.

Related Links:

University of Texas
Luminex
GTI



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.